AAA Screening in Men Over 65 Reduces Mortality

screening abdominal aortic aneurysmSystematic screening for abdominal aortic aneurysm (AAA) targeting all men over 65 years old (not just those presenting risk factors) was associated with a drop in the mortality rate specific for this disease, according to the Swedish Nationwide Screening Program.

 

While 667 men were examined for AAA, the number of patients who required treatment to prevent premature death due to aneurysm rupture was merely 1.5.

 

Such amazing treatment efficacy justifies screening despite the relatively low prevalence of this disease.

 

Randomized studies showed that screening through ultrasound followed by preventive surgery can reduce associated mortality in selected populations, but such a selection differs by location. This is, precisely, the novelty in this study: no selection was made; all men over 65 years old were studied.

 

In this registry, of 302,957 men who received an invitation to be screened, 84% finally accepted, a very high percentage.

 

AAA was detected in 1.5% of men, 29% of which underwent preventive surgery over a mean follow-up of 4.5 years.

 

Mortality at 30 days was significantly lower for endovascular treatment compared to open surgery.

 

Endovascular treatment: 0.3%

Open surgery:  1.3%

(p <0.001)

 

There was a significant reduction in mortality (4%) per year of screening (p = 0.02).

 

From 2000 (before the introduction of screening) to 2014, associated mortality dropped from 74 to 45 patients every 100,000 subjects.

 

Conclusion

Systematic screening for abdominal aortic aneurysm in men over 65 years old is highly cost-effective and reduces mortality associated to aneurysm rupture.

 

Original title: Outcome of the Swedish nationwide abdominal aortic aneurysm screening program.

Reference: Wanhainen A et al. Circulation 2016; Epub ahead of print.

 

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

A New Asymptomatic Carotid Stenosis Paradigm? CREST-2 Trial Unified Results

Severe asymptomatic carotid stenosis continues to be controversial seeing the optimization of intensive medical therapy (IMT) and the availability lower periprocedural risk revascularization techniques....

Impact of Baseline Systolic Blood Pressure on Blood Pressure Changes Following Renal Denervation

Renal denervation (RDN) is a guideline-recommended therapy to reduce blood pressure in patients with uncontrolled hypertension, although uncertainties remain regarding which factors best predict...

Hypertriglyceridemia as Key Factor to Abdominal Aortic Aneurysm Development and Rupture: Genetic and Experimental Evidence

Abdominal aortic aneurysm (AAA) is a deadly vascular disease with no effective drug treatment, and risk of rupture reaching up to 80%. Even though...

Atrial Fibrillation and Chronic Kidney Disease: Outcomes of Different Stroke Prevention Strategies

Atrial fibrillation (AF) affects approximately 1 in every 4 patients with end-stage renal disease (ESRD). This population carries a high burden of comorbidities and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...